IP Library Granted Patent US 7,982,067
Granted Patent B2
US 7,982,067 · App. 12/836,025 · Granted Jul 19, 2011

Phenethanolamine derivatives for treatment of respiratory diseases

Assignee: Glaxo Group Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,982,067
App. No.
12/836,025
Granted
Jul 19, 2011
Kind
B2
Abstract

Compounds of the formula (II) and (IV) are provided, which may be employed as intermediates for making compounds useful in treating respiratory diseases.

Claims (112)

1. A compound of formula (II):

or a salt thereof, wherein

m is an integer of from 2 to 8;

n is an integer of from 2 to 5;

with the proviso that m+n is 4 to 10;

R 1a , R 2a , and R 3a are each independently either the same as R 1 , R 2 , and R 3 respectively as defined below or represent a precursor for said group R 1 , R 2 , or R 3 ;

R 1 is selected from hydrogen, C 1-6 alkyl, hydroxy, halo, C 1-6 haloalkyl,

—XC(O)NR 9 R 10 , —XNR 8 C(O)R 9 , —XNR 8 C(O)NR 9 R 10 , —XNR 8 SO 2 R 9 , —XSO 2 NR 11 R 12 , XNR 8 SO 2 R 9 R 10 ,

—XNR 9 R 10 , XN + R 8 R 9 R 10 , —XNR 8 C(O)OR 9 , —XCO 2 R 9 , —XNR 8 C(O)NR 8 C(O)NR 9 R 10 , —XSR 9 , XSOR 9 , and —XSO 2 R 9 ;

or R 1 is selected from —X-aryl, —X-hetaryl, and —X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C 1-6 alkoxy, halo, C 1-6 alkyl,

C 1-6 haloalkyl, —NHC(O)(C 1-6 alkyl), —SO 2 (C 1-6 alkyl), —SO 2 (aryl), —SO 2 NH 2 , —SO 2 NH(C 1-6 alkyl), —SO 2 NH(C 3-7 cycloalkyl), —CO 2 H, —CO 2 (C 1-6 alkyl), —SO 2 NH(C 3-7 cycloalkylC 1-6 alkyl), —NH 2 , —NH(C 1-6 alkyl), or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C 1-6 alkoxy, halo, C 1-6 alkyl, or

C 1-6 haloalkyl;

X is —(CH 2 ) p — or C 2-6 alkenylene;

p is an integer from 0 to 6,

R 8 and R 9 are independently selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, hetaryl, hetaryl(C 1-6 alkyl)- and aryl(C 1-6 alkyl)- and R 8 and R 9 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C 1-6 alkyl,

C 1-6 haloalkyl, —NHC(O)(C 1-6 alkyl), —SO 2 (C 1-6 alkyl), —SO 2 (aryl), —CO 2 H, —CO 2 (C 1-4 alkyl),

—NH 2 , —NH(C 1-6 alkyl), aryl(C 1-6 alkyl)-, aryl(C 2-6 alkenyl)-, aryl(C 2-6 alkynyl)-, hetaryl(C 1-6 alkyl)-, —NHSO 2 aryl, —NH(hetarylC 1-6 alkyl), —NHSO 2 hetaryl, —NHSO 2 (C 1-6 alkyl), —NHC(O)aryl, or —NHC(O)hetaryl:

R 10 is selected from hydrogen, C 1-6 alkyl and C 3-7 cycloalkyl;

R 11 and R 12 are independently selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, hetaryl, hetaryl(C 1-6 alkyl)- and aryl(C 1-6 alkyl)-, or R 11 and R 12 , together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring;

and R 11 and R 12 are each optionally substituted by one or two groups independently selected from halo, C 1-6 alkyl, and C 1-6 haloalkyl;

where R 1 is —XNR 8 C(O)NR 9 R 10 , R 8 and R 9 may, together with the —NC(O)N— portion of the group R 1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring;

where R 1 is —XNR 8 C(O)OR 9 , R 8 and R 9 may, together with the —NC(O)O— portion of the group R 1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring;

where R 1 is —XC(O)NR 9 R 10 or —XNR 8 C(O)NR 9 R 10 , R 9 and R 10 may, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring;

R 2 is selected from hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo, aryl, aryl(C 1-6 alkyl)-, C 1-6 haloalkoxy, and C 1-6 haloalkyl;

R 3 is selected from hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo, aryl, aryl(C 1-6 alkyl)-, C 1-6 haloalkoxy, and C 1-6 haloalkyl;

R 4 and R 5 are independently selected from hydrogen and C 1-4 alkyl with the proviso that the total number of carbon atoms in R 4 and R 5 is not more than 4; and,

R 6 and R 7 are independently selected from hydrogen and C 1-4 alkyl with the proviso that the total number of carbon atoms in R 6 and R 7 is not more than 4;

and R 13 , R 14 , and R 15 are each independently either hydrogen or a protecting group provided that at least one of R 13 , R 14 , and R 15 is a protecting group, and R 19 is hydrogen or a protecting group.

2. A compound of formula (II) according to claim 1 or a salt thereof wherein R 1 is selected from hydrogen, C 1-6 alkyl, hydroxy, halo, C 1-6 haloalkyl, —XNR 8 (C)OR 9 , —XNR 8 C(O)NR 9 R 10 , —XNR 8 SO 2 R 9 , —XSO 2 NR 11 R 12 , —XNR 9 R 10 , —XNR 8 C(O)OR 9 , XSR 9 , XSOR 9 , XSO 2 R 9 , or from X-aryl, X-hetaryl or X-aryloxy, optionally substituted.

3. A compound of formula (II) according to claim 1 or a salt thereof wherein X is (CH 2 ) p wherein p is zero.

4. A compound of formula (II) according to claim 1 or a salt thereof wherein R 1 is selected from hydrogen, C 1-4 alkyl, hydroxy, halo, —NR 8 C(O)NR 9 R 10 , and —NR 8 SO 2 R 9 .

5. A compound of formula (II) according to claim 1 or a salt thereof wherein R 2 and R 3 are independently selected from hydrogen, halogen, haloC 1-6 alkyl, C 1-6 alkyl, and phenyl or substituted phenyl.

6. A compound of formula (II) according to claim 1 or a salt thereof wherein R 1 is not XNR 8 SO 2 R 9 R 10 , XN + R 8 R 9 R 10 , —XCO 2 R 9 , —XNR 8 C(O)NR 8 C(O)NR 9 R 10 , —XSR 9 , XSOR 9 , or —XSO 2 R 9 .

7. A compound of formula (II) according to claim 1 or a salt thereof wherein the group R 1 is attached to the meta-position relative to the —OCR 6 R 7 — link.

8. A compound of formula (II) according to claim 1 or a salt thereof wherein the groups R 2 and R 3 are each independently attached to the ortho-position relative to the —OCR 6 R 7 -link.

9. A compound of formula (II) according to claim 8 or a salt thereof wherein R 1 represents a substituent other than hydrogen, attached to the meta-position relative to the —OCR 6 R 7 -link, and R 2 and R 3 each represent hydrogen.

10. A compound of formula (II) according to claim 1 or a salt thereof wherein R 1 represents hydrogen and R 2 and R 3 each represent a substituent at least one of which is other than hydrogen, and R 2 and R 3 are each independently attached to the ortho- or meta-positions relative to the —OCR 6 R 7 -link.

11. A compound of formula (II) according to claim 10 , or a salt thereof, wherein R 2 and R 3 each represent halogen attached to the ortho position relative to the —OCR 6 R 7 -link.

12. A compound of formula (II) according to claim 1 or a salt thereof wherein R 4 and R 5 are independently selected from hydrogen and methyl.

13. A compound of formula (II) according to claim 1 or a salt thereof wherein R 6 and R 7 are independently selected from hydrogen and methyl.

14. A compound of formula (II) according to claim 1 or a salt thereof wherein m is 4, 5 or 6, and n is 2 or 3.

15. A compound according to claim 1 wherein R 13 and R 14 together represent a protecting group R 16 R 17 C═ as in the compound of formula (III):

or a salt thereof, wherein R 1a , R 2a , R 3a , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , m, and n are as defined for the compound of formula (II).

16. A compound selected from the group consisting of:

N-[3-({2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]ethoxy}methyl)phenyl]-N′-phenylurea; and

(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol;

N-cyclohexyl-N′-[3-({2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]ethoxy}methyl)phenyl]urea;

N-(1,1′-biphenyl-4-yl)-N′-[3-({2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]ethoxy}methyl)phenyl]urea;

N-cyclopropyl-3′-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]ethoxy)methyl]-1,1′-biphenyl-2-sulfonamide;

(1R)-2-{[6-(2-[{3-(2,3-dihydroimidazo[2,1-b][1,3]thiazol-6-ylmethyl)amino]-phenyl}methoxy]ethoxy)hexyl]amino}-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol;

N-{3-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-amino}hexyl)oxy]ethoxy)methyl]phenyl}-3-[(phenylsulfonyl)amino]benzamide;

N-(3-{[({3-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxy-ethyl]amino}hexyl)oxy]ethoxy)methyl]phenyl}amino)carbonyl]amino}phenyl)-pyridine-3-carboxamide;

N-cyclohexyl-3-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]ethoxy)methyl]-N-({[2-(trimethylsilyl)ethyl]-oxy}methyl)benzenesulfonamide;

3′-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl]-amino}hexyl)oxy]ethoxy)methyl]-1,1′-biphenyl-3-ol;

(1R)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-[(6-{2-[(3-iodobenzyl)oxy]-ethoxy}hexyl)amino]ethanol;

N-{3-[(2-{[6-({(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}-amino)hexyl]oxy}ethoxy)methyl]phenyl}-N′-[3-(phenylethynyl)phenyl]urea;

(1R)-2-{[6-(2-{[3′-{2,4-bis[(1,1-dimethylethyl)oxy]pyrimidin-5-yl}-1,1′-biphenyl-3-yl]methoxy}ethoxy)hexyl]amino}-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol; and

cyclopentyl 3-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxy-ethyl]amino}hexyl)oxy]ethoxy)methyl]phenylcarbamate.

17. A compound of formula (IV):

or a salt thereof, wherein

m is an integer of from 2 to 8;

n is an integer of from 2 to 5;

with the proviso that m+n is 4 to 10;

R 1a , R 2a , and R 3a are each independently either the same as R 1 , R 2 , and R 3 respectively as defined below or represent a precursor for said group R 1 , R 2 , or R 3 ;

R 1 is selected from hydrogen, C 1-6 alkyl, hydroxy, halo, C 1-6 haloalkyl,

—XC(O)NR 9 R 10 , —XNR 8 C(O)R 9 , —XNR 8 C(O)NR 9 R 10 , —XNR 8 SO 2 R 9 , —XSO 2 NR 11 R 12 , XNR 8 SO 2 R 9 R 10 ,

—XNR 9 R 10 , XN + R 8 R 9 R 10 , —XNR 8 C(O)OR 9 , —XCO 2 R 9 , —XNR 8 C(O)NR 8 C(O)NR 9 R 10 , —XSR 9 , XSOR 9 , and —XSO 2 R 9 ;

or R 1 is selected from —X-aryl, —X-hetaryl, and —X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C 1-6 alkoxy, halo, C 1-6 alkyl,

C 1-6 haloalkyl, —NHC(O)(C 1-6 alkyl), —SO 2 (C 1-6 alkyl), —SO 2 (aryl), —SO 2 NH 2 , —SO 2 NH(C 1-6 alkyl), —SO 2 NH(C 3-7 cycloalkyl), —CO 2 H, —CO 2 (C 1-6 alkyl), —SO 2 NH(C 3-7 cycloalkylC 1-6 alkyl), —NH 2 , —NH(C 1-6 alkyl), or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C 1-6 alkoxy, halo, C 1-6 alkyl, or

C 1-6 haloalkyl;

X is —(CH 2 ) p — or C 2-6 alkenylene;

p is an integer from 0 to 6,

R 8 and R 9 are independently selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, hetaryl, hetaryl(C 1-6 alkyl)- and aryl(C 1-6 alkyl)- and R 8 and R 9 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C 1-6 alkyl,

C 1-6 haloalkyl, —NHC(O)(C 1-6 alkyl), —SO 2 (C 1-6 alkyl), —SO 2 (aryl), —CO 2 H, —CO 2 (C 1-4 alkyl),

—NH 2 , —NH(C 1-6 alkyl), aryl(C 1-6 alkyl)-, aryl(C 2-6 alkenyl)-, aryl(C 2-6 alkynyl)-, hetaryl(C 1-6 alkyl)-, —NHSO 2 aryl, —NH(hetarylC 1-6 alkyl), —NHSO 2 hetaryl, —NHSO 2 (C 1-6 alkyl), —NHC(O)aryl, or —NHC(O)hetaryl:

R 10 is selected from hydrogen, C 1-6 alkyl and C 3-7 cycloalkyl;

R 11 and R 12 are independently selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, hetaryl, hetaryl(C 1-6 alkyl)- and aryl(C 1-6 alkyl)-, or R 11 and R 12 , together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring;

and R 11 and R 12 are each optionally substituted by one or two groups independently selected from halo, C 1-6 alkyl, and C 1-6 haloalkyl;

where R 1 is —XNR 8 C(O)NR 9 R 10 , R 8 and R 9 may, together with the —NC(O)N— portion of the group R 1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring;

where R 1 is —XNR 8 C(O)OR 9 , R 8 and R 9 may, together with the —NC(O)O— portion of the group R 1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring;

where R 1 is —XC(O)NR 9 R 10 or —XNR 8 C(O)NR 9 R 10 , R 9 and R 10 may, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring;

R 2 is selected from hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo, aryl, aryl(C 1-6 alkyl)-, C 1-6 haloalkoxy, and C 1-6 haloalkyl;

R 3 is selected from hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, halo, aryl, aryl(C 1-6 alkyl)-, C 1-6 haloalkoxy, and C 1-6 haloalkyl;

R 4 and R 5 are independently selected from hydrogen and C 1-4 alkyl with the proviso that the total number of carbon atoms in R 4 and R 5 is not more than 4; and,

R 6 and R 7 are independently selected from hydrogen and C 1-4 alkyl with the proviso that the total number of carbon atoms in R 6 and R 7 is not more than 4;

and R 13 , R 14 , and R 15 are each independently either hydrogen or a protecting group provided that at least one of R 13 , R 14 , and R 15 is a protecting group, and R 19 is hydrogen or a protecting group.

18. A compound selected from the group consisting of:

(5R)-3-(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one;

(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-(6-{2-[(3-nitrobenzyl)oxy]-ethoxy}hexyl)-1,3-oxazolidin-2-one;

N-(3-{[2-({6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy]methyl}phenyl)-N′-phenylurea;

N-cyclohexyl-M-(3-{[2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy]methyl}phenyl)urea;

N-(1,1′-biphenyl-4-yl)-N′-(3-{[2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy]methyl}phenyl)urea;

(5R)-3-(6-{2-[(3-aminobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one;

(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[2-{[(3-nitrophenyl)-methyl]oxy}ethoxy]hexyl}-1,3-oxazolidin-2-one;

N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]-3-[(phenylsulfonyl)amino]-benzamide;

3-amino-N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]benzamide;

N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]-3-nitrobenzamide;

N-(3-aminophenyl)-N′-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]urea;

N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]-N′-(3-nitrophenyl)urea;

N-cyclohexyl-3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)-N-({[2-(trimethylsilyl)ethyl]oxy}-methyl)benzenesulfonamide;

N-{3-[({[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]amino}carbonyl)amino]-phenyl}pyridine-3-carboxamide;

cyclopentyl 3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenylcarbamate;

N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]-N′-[3-(phenylethynyl)phenyl]urea;

1,1-dimethylethyl cyclopropyl{[3′-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)-1,1′-biphenyl-2-yl]sulfonyl}carbamate;

(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-(6-{2-([3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methoxy)ethoxy}hexyl)-1,3-oxazolidin-2-one;

(5R)-3-[6-(2-[{3-[(2,3-dihydroimidazo[2,1-b][1,3]thiazol-6-ylmethyl)amino]-phenyl}methoxy]ethoxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one;

(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[2-{(3-iodophenyl)methoxy}ethoxy]hexyl}-1,3-oxazolidin-2-one;

(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[2-{(3′-hydroxy-1,1′-biphenyl-3-yl)methoxy}ethoxy]hexyl}-1,3-oxazolidin-2-one; and

(5R)-3-{6-[2-{(3′-{2,4-bis[(1,1-dimethylethyl)oxy]pyrimidin-5-yl}-1,1′-biphenyl-3-yl)methoxy}ethoxy]hexyl}-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one.

19. A compound according to claim 17 wherein R 13 and R 14 are independently selected from an ester.

20. A compound according to claim 17 wherein R 15 represents a group selected from benzyl, α-methylbenzyl, diphenylmethyl, triphenylmethyl, benzyloxycarbonyl, tert-butoxycarbonyl, trichloroacetyl, and trifluoroacetyl.

21. A compound of according to claim 17 wherein R 19 represents a trialkylsilyl group.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2013
From: BOX, PHILIP CHARLES; COE, DIANE MARY; LOOKER, BRIAN EDGAR; MANN, INDERJIT SINGH; PROCOPIOU, PANAYIOTIS ALEXANDROU
To: GLAXO GROUP LIMITED
Reel/Frame 029903/0936 →
Priority Claims (2)
GB 0122201.7 · Sep 14, 2001 · national
GB 0126997.6 · Nov 9, 2001 · national
Continuity (4)
Continuation 12211322 · Sep 16, 2008
Continuation 11566346 · Dec 4, 2006
Continuation 10489569
Related Publication 20110009631A1 · Jan 13, 2011